دورية أكاديمية
Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.
| العنوان: | Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study. |
|---|---|
| المؤلفون: | Bonora BM; Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.; Veneto Institute of Molecular Medicine, Padua, Italy., Russo G; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy., Leonetti F; Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy., Strazzabosco M; Diabetology and Metabolic Diseases Unit, S. Bortolo Hospital, Vicenza, Italy., Nollino L; Department of Medicine, Diabetology Service, Azienda ULSS 2 Marca Trevigiana, Treviso, Italy., Aimaretti G; Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy., Giaccari A; Centro per le Malattie Endocrine e Metaboliche, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy., Broglio F; Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy., Consoli A; Endocrinology and Metabolism Unit, ASL, Pescara, Italy.; Department of Medicine and Aging Sciences DMSI and Center for Advanced Studies and Technology CAST, 'G. D'Annunzio' University of Chieti-Pescara, Chieti, Italy., Avogaro A; Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy., Fadini GP; Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy. gianpaolo.fadini@unipd.it.; Veneto Institute of Molecular Medicine, Padua, Italy. gianpaolo.fadini@unipd.it. |
| مؤلفون مشاركون: | GLIMPLES Study Investigators |
| المصدر: | Journal of endocrinological investigation [J Endocrinol Invest] 2024 Jun; Vol. 47 (6), pp. 1395-1403. Date of Electronic Publication: 2024 Feb 18. |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: Italy NLM ID: 7806594 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1720-8386 (Electronic) Linking ISSN: 03914097 NLM ISO Abbreviation: J Endocrinol Invest Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Berlin : Springer Original Publication: Milano, Published for the Italian Society of Endocrinology by Editrice Kurtis. |
| مواضيع طبية MeSH: | Glucagon-Like Peptides*/administration & dosage , Glucagon-Like Peptides*/therapeutic use , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/blood , Body Weight*/drug effects , Hypoglycemic Agents*/administration & dosage , Hypoglycemic Agents*/therapeutic use , Blood Glucose*/drug effects , Blood Glucose*/analysis , Blood Glucose*/metabolism, Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Administration, Oral ; Aged ; Glycated Hemoglobin/analysis ; Glycemic Control/methods ; Treatment Outcome ; Follow-Up Studies |
| مستخلص: | Aim: Oral semaglutide, an innovative orally administered GLP-1 receptor agonist for type 2 diabetes (T2D) management was herein evaluated for its effectiveness in a multi-center retrospective real-world study. Methods: We included new-users of oral semaglutide from 18 specialist care centres and collected retrospective data on baseline clinical characteristics. Updated values of HbA1c and body weight were analyzed using the mixed model for repeated measures. Results: The study included 166 individuals with T2D, predominantly men (64.5%), with a mean age of 64.4 years and a mean diabetes duration of 10.1 years. In the majority of patients (68.3%) oral semaglutide was used as a second-line drug, mostly with metformin. At baseline, mean BMI was 28.9 kg/m 2 and HbA1c was 7.5%. During the 18-month observation period, oral semaglutide demonstrated significant reductions in HbA1c, with a maximum change of - 0.9%, and 42.1% of patients achieved HbA1c values below 7.0%. Additionally, there was a substantial reduction in body weight, with an estimated change of - 3.4 kg at 18 months, and 30.3% of patients experienced a 5% or greater reduction in baseline body weight. Only 24.2% of patients reached the 14 mg dose. Subgroup analysis revealed that baseline HbA1c > 7%, persistence on drug, not being on a prior therapy with DPP-4 inhibitors, and loosing 5% or more the initial body weight were associated with greater HbA1c reductions. Conclusion: This study supports oral semaglutide as an effective option for T2D treatment, offering improved glucose control and weight management in a real-world setting. (© 2024. The Author(s).) |
| References: | Acta Diabetol. 2020 Mar;57(3):367-375. (PMID: 31673896) Diabetes Obes Metab. 2023 Jul;25(7):1813-1822. (PMID: 36855221) J Cardiovasc Dev Dis. 2023 Apr 18;10(4):. (PMID: 37103055) J Clin Med. 2023 Sep 19;12(18):. (PMID: 37762991) Diabetes Obes Metab. 2021 Sep;23(9):2177-2182. (PMID: 34060209) Diabetologia. 2020 Mar;63(3):473-485. (PMID: 31897524) Front Endocrinol (Lausanne). 2021 Jun 29;12:645507. (PMID: 34267725) Cardiovasc Diabetol. 2016 Apr 02;15:55. (PMID: 27039303) Am J Manag Care. 2020 Dec;26(16 Suppl):S335-S343. (PMID: 33439582) Diabetes Obes Metab. 2023 Jul;25(7):1932-1941. (PMID: 36945734) Diabetes Ther. 2023 Dec;14(12):2159-2172. (PMID: 37848758) N Engl J Med. 2019 Aug 29;381(9):841-851. (PMID: 31185157) N Engl J Med. 2016 Nov 10;375(19):1834-1844. (PMID: 27633186) Cardiovasc Diabetol. 2022 Sep 2;21(1):172. (PMID: 36056351) Diabetes Care. 2019 Dec;42(12):2272-2281. (PMID: 31530666) Diabetes Care. 2024 Jan 1;47(Suppl 1):S145-S157. (PMID: 38078578) Sci Transl Med. 2018 Nov 14;10(467):. (PMID: 30429357) BMJ. 2021 Jan 13;372:m4573. (PMID: 33441402) Cardiol Res. 2022 Oct;13(5):303-308. (PMID: 36405226) Adv Ther. 2023 Nov;40(11):5102-5114. (PMID: 37740832) Diabetes Res Clin Pract. 2023 May;199:110672. (PMID: 37084893) Cell Rep Med. 2021 Sep 03;2(9):100387. (PMID: 34622228) |
| فهرسة مساهمة: | Keywords: Body weight; Glucose control; Oral semaglutide; Real-world effectiveness; Retrospective study; Type 2 diabetes |
| المشرفين على المادة: | 53AXN4NNHX (semaglutide) 62340-29-8 (Glucagon-Like Peptides) 0 (Hypoglycemic Agents) 0 (Blood Glucose) 0 (Glycated Hemoglobin) 0 (hemoglobin A1c protein, human) |
| تواريخ الأحداث: | Date Created: 20240218 Date Completed: 20240601 Latest Revision: 20240719 |
| رمز التحديث: | 20240720 |
| مُعرف محوري في PubMed: | PMC11142994 |
| DOI: | 10.1007/s40618-024-02309-2 |
| PMID: | 38369592 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1720-8386 |
|---|---|
| DOI: | 10.1007/s40618-024-02309-2 |